Antagonizing BCL-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Olsen, Rachelle R ^a   Mary Sinclair, Michelle N ^a   Yin, Zhirong ^a   Freeman, Kevin W ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; CASPASE 3; CASPASE INHIBITOR; MYC PROTEIN; NAVITOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; QVD; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; CASPASE; GLUTAMINE; SULFONAMIDE;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; EWING SARCOMA; EWING SARCOMA CELL LINE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN EXPRESSION; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; HUMAN; METABOLISM; SARCOMA, EWING; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BONE NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DIAZOOXONORLEUCINE; DRUG SYNERGISM; GLUTAMINE; HUMANS; MICE; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; SARCOMA, EWING; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921799428     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116998     Document Type: Article

References (31)

1. Howlader NNA, Krapcho M, Neyman N, Aminou R, Waldron W, et al. (2011). SEER Cancer Statistics Review, 1975-2008. Editor (ed)(eds): City.
2. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation Cell Metab 7, 11-20. doi: 10.1016/j.cmet.2007.10.002 PMID: 18177721
3. Koppenol WH, Bounds PL, Dang CV (2011). Otto Warburg's contributions to current concepts of cancer metabolism Nat Rev Cancer 11, 325-337. doi: 10.1038/nrc3108 PMID: 21508971
4. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008). Brick by brick: metabolism and tumor cell growth Curr Opin Genet Dev 18, 54-61. doi: 10.1016/j.gde.2008.02.003 PMID: 18387799
5. Vander Heiden MG, Cantley LC, Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324, 1029-1033. doi: 10.1126/science.1160809 PMID: 19460998
6. Ward PS, Thompson CB (2012). Metabolic reprogramming: a cancer hallmark even warburg did not anticipate Cancer Cell 21, 297-308. doi: 10.1016/j.ccr.2012.02.014 PMID: 22439925
7. Liu W, Le A, Hancock C, Lane AN, Dang CV, et al. (2012). Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC Proc Natl Acad Sci U S A 109, 8983-8988. doi: 10.1073/pnas.1203244109 PMID: 22615405
8. Qing G, Li B, Vu A, Skuli N, Walton ZE, et al. (2012). ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation Cancer Cell 22, 631-644. doi: 10.1016/j.ccr.2012.09.021 PMID: 23153536
9. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, et al. (2009). International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee Br J Cancer 100, 1471-1482. doi: 10.1038/sj.bjc.6605014 PMID: 19401703
10. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J (2009). Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res 69, 7140-7150. doi: 10.1158/0008-5472.CAN-08-4041 PMID: 19738075
11. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, et al. (2005). Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells Cancer Res 65, 11459-11468. doi: 10. 1158/0008-5472.CAN-05-1696 PMID: 16357154
12. Liu YC, Li F, Handler J, Huang CR, Xiang Y, et al. (2008). Global regulation of nucleotide biosynthetic genes by c-Myc PLoS One 3, e2722. doi: 10.1371/journal.pone.0002722 PMID: 18628958
13. Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery DM (2009). c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry Oncogene 28, 2485-2491. doi: 10.1038/onc.2009. 112 PMID: 19448666
14. Dang CV (2011). Therapeutic targeting of Myc-reprogrammed cancer cell metabolism Cold Spring Harb Symp Quant Biol 76, 369-374. doi: 10.1101/sqb.2011.76.011296 PMID: 21960526
15. Wise DR, Thompson CB (2010). Glutamine addiction: a new therapeutic target in cancer Trends Biochem Sci 35, 427-433. doi: 10.1016/j.tibs.2010.05.003 PMID: 20570523
16. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G (2013). Metabolic targets for cancer therapy Nat Rev Drug Discov 12, 829-846. doi: 10.1038/nrd4145 PMID: 24113830
17. Ganapathy-Kanniappan S, Geschwind JF (2013). Tumor glycolysis as a target for cancer therapy: progress and prospects Mol Cancer 12, 152. doi: 10.1186/1476-4598-12-152 PMID: 24298908
18. Kisner DL, Catane R, Muggia FM (1980). The rediscovery of DON (6-diazo-5-oxo-L-norleucine) Recent Results Cancer Res 74, 258-263. doi: 10.1007/978-3-642-81488-4 30 PMID: 7192426
19. Sullivan MP, Nelson JA, Feldman S, Van Nguyen B (1988). Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children Cancer Chemother Pharmacol 21, 78-84. doi: 10.1007/BF00262746 PMID: 3342470
20. Dunn T, Praissman L, Hagag N, Viola MV (1994). ERG gene is translocated in an Ewing's sarcoma cell line Cancer Genet Cytogenet 76, 19-22. doi: 10.1016/0165-4608(94)90063-9 PMID: 8076344
21. Ramanathan A, Wang C, Schreiber SL (2005). Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements Proc Natl Acad Sci U S A 102, 5992-5997. doi: 10.1073/pnas. 0502267102 PMID: 15840712
22. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, et al. (2007). Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis Proc Natl Acad Sci U S A 104, 19345-19350. doi: 10.1073/pnas.0709747104 PMID: 18032601
23. Saqcena M, Mukhopadhyay S, Hosny C, Alhamed A, Chatterjee A, et al. (2014). Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs Oncogene.
24. Le A, Lane AN, Hamaker M, Bose S, Gouw A, et al. (2012). Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells Cell Metab 15, 110-121. doi: 10.1016/j. cmet.2011.12.009 PMID: 22225880
25. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, et al. (2011). Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors J Clin Oncol 29, 909-916. doi: 10.1200/JCO.2010.31.6208 PMID: 21282543
26. Novick SJ (2013). A simple test for synergy for a small number of combinations Stat Med 32, 5145-5155. doi: 10.1002/sim.5905 PMID: 23904140
27. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. (2013). Cellular fatty acid metabolism and cancer Cell Metab 18, 153-161. doi: 10.1016/j.cmet.2013.05.017 PMID: 23791484
28. Biswas S, Lunec J, Bartlett K (2012). Non-glucose metabolism in cancer cells-is it all in the fat? Cancer Metastasis Rev 31, 689-698. doi: 10.1007/s10555-012-9384-6 PMID: 22706846
29. DeBerardinis RJ, Cheng T (2010). Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer Oncogene 29, 313-324. doi: 10.1038/onc.2009.358 PMID: 19881548
30. Bodur C, Basaga H (2012). Bcl-2 inhibitors: emerging drugs in cancer therapy Curr Med Chem 19, 1804-1820. doi: 10.2174/092986712800099839 PMID: 22414090
31. Chin YR, Yuan X, Balk SP, Toker A (2014). PTEN-Deficient Tumors Depend on AKT2 for Maintenance and Survival Cancer Discov.